WCLC: Tagrisso's chemo combo shows edge, but AstraZeneca thinks monotherapy remains king in lung cancer

AstraZeneca’s Tagrisso is the standard of care in newly diagnosed, EGFR-mutated non-small cell lung cancer (NSCLC). The company hopes to offer a new combination with chemotherapy, but the lack of patient survival showing may be a problem for that effort.